Evaluation of the preference, satisfaction and correct use of Breezhaler® and Respimat® inhalers in patients with chronic obstructive pulmonary disease – INHALATOR study. (November 2018)

• Record Type: Journal Article
• Authors: Oliveira, Maria Vera Cruz de; Pizzichini, Emilio; da Costa, Claudia Henrique; Fritscher, Carlos Cezar; Vianna, Elcio Oliveira; Teixeira, Paulo José Zimermann; Stirbulov, Roberto; Rabahi, Marcelo Fouad; Pinho, Nadine Cordeiro de
• Is Part Of: Respiratory medicine. Volume 144(2018)
• Page Start: 61
• Page End: 67
• Publication Date: 2018-11
• Subjects: Chronic obstructive pulmonary disease -- Patient preference -- Patient satisfaction -- Administration -- Inhaler preference -- Inhaler device; Chest -- Diseases -- Periodicals; Chest -- Diseases -- Great Britain -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Appareil respiratoire -- Maladies -- Périodiques; Thorax -- Maladies -- Périodiques; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Electronic journals; 616.2
• DOI: 10.1016/j.rmed.2018.10.006
• Languages: English
• ISSNs: 0954-6111

Abstract

Abstract: The INHALATOR study was a randomized, multicentre, open label, two-period of 7 days each, crossover study, with 7 days of washout in-between, aiming to evaluate the correct use, satisfaction and preference between Breezhaler ® and Respimat ® devices in patients under daily use of open Spiriva ® or open Onbrize ®, as monotherapy for treatment of mild or moderate COPD. Patients aged ≥40 years with a smoking history of at least 10 pack-year were included in the study. Primary endpoint was the rate of correct use of each device at the first day of treatment after reading the drug leaflet information and was evaluated under the supervision of a trained evaluator. At the end of each treatment phase, the inhaler use was re-evaluated and a satisfaction questionnaire was completed. The patients' preference for the inhaler devices was assessed at the end of the study. After exclusions due to screening failures, 140 patients were randomized: 136 received at least one dose of Breezhaler ® and 135 of Respimat ® . At treatment start, the rate of correct inhaler use was 40.4% (95%CI: 32.2%–48.7%) for Breezhaler ® and 36.3% (95%CI: 28.2%–44.4%) for Respimat ® (p = 0.451). After 7 days, the rates were 68.9% (95%CI: 61.1%–76.7%) and 60.4% (95%CI: 52.2%–68.7%), respectively (p = 0.077). According to the Feeling of Satisfaction with Inhaler Questionnaire - FSI 10 patients were more satisfied using Breezhaler ® than Respimat ® and 57.1% preferred using Breezhaler ® (p = 0.001) while 30.1% preferred Respimat ® (p < 0.001). Highlights: A majority of the patients preferred the Breezhaler ® over Respimat ® . Patients showed a higher satisfaction with Breezhaler ® compared with the Respimat ® . A high prevalence of inappropriate use of the devices was observed in both groups. There was no difference between the patients who did not make critical errors.